摘要
目的探讨培美曲塞+顺铂治疗非小细胞肺癌(NSCLC)的疗效,为NSCLC的新辅助化疗提供参考。方法将2014年1月至2015年6月治疗的Ⅳ期NSCLC患者90例按随机数字表法分为两组,每组45例,对照组按多西他赛+顺铂方案化疗,研究组前瞻性给予培美曲塞+顺铂方案化疗,化疗前、后检测两组肿瘤标志物及表皮生长因子受体(EGFR)基因突变情况,比较治疗效果及毒副反应发生情况。结果两组实体瘤治疗有效率比较差异无统计学意义(P>0.05);研究组中位无进展生存期(PFS)长于对照组(P<0.05);研究组化疗后血清癌胚抗原(CEA)、CYFRA21-1浓度显著低于化疗前及对照组(P<0.05);两组化疗前、后EGFR突变阳性率比较差异无统计学意义(P>0.05);两组毒副反应发生率比较差异无统计学意义(P>0.05)。结论培美曲塞+顺铂化疗治疗晚期肺癌的疗效与一线化疗相当,但新辅助化疗可延长PFS,其对EGFR基因突变状态变化无明显影响。
Objective To investigate the effect of pemetrexed combined with cisplatin therapy for patients with NSCLC and provide areference for NSCLC neoadjuvant chemotherapy.Methods90patients with NSCLC at stageⅣin January2014to June2015were randomlydivided into two groups,45patients in each group.The patients in control group received docetaxel combined with cisplatin chemotherapy,while the study group received pemetrexed combined with cisplatin chemotherapy.Tumor markers and EGFR gene mutation were detected,the therapeutic effect and toxicity for patients were compared.Results Solid tumor treatment efficiency had no statistically significant differencebetween the two group after treatment(P>0.05);median PFS of patients in the study group was longer than that in the control group(P<0.05);after chemotherapy,serum CEA,CYFRA21-1concentrations of patients in the study group were significantly lower than thosebefore chemotherapy and those in the control group(P<0.05);the EGFR mutation positive rate had no statistically significant differencebefore and after chemotherapy(P>0.05);the incidence of adverse reactions had no statistically significant difference(P>0.05).ConclusionThe effect of pemetrexed combined with cisplatin chemotherapy for patients with advanced NSCLC on solid tumor efficacy is fair to first-linechemotherapy,but neoadjuvant chemotherapy can prolong PFS of patients,but the mutation status of the EGFR gene variation has no significanteffect.
作者
吴菲
薛蔚洁
施怡芳
刘丽锋
范梦瑶
WU Fei;XUE Weijie;SHI Yifang;LIU Lifeng;FAN Mengyao(Department of Pharmacy, the Affiliated Wuxi No.2 Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, China)
出处
《肿瘤药学》
CAS
2017年第5期576-580,共5页
Anti-Tumor Pharmacy
基金
江苏省卫生厅预防医学科研课题(Y2013067)
关键词
非小细胞肺癌
培美曲塞/顺铂
表皮生长因子受体
基因突变
Non-small cell lung cancer
Pemetrexed/cisplatin
Epidermal growth factor receptor
Gene mutation
